Recently, our laboratory investigated the therapeutic potential of a novel reversible and non-competitive LSD1 inhibitor (HCI-2509, Salarius Pharmaceuticals) for the treatment of Ewing sarcoma. Here, KDM1A is linked to Ewing sarcoma.